Medigen to begin phase 2 vaccine candidate trials
By Kao Shih-ching / Staff reporter
Medigen Vaccine Biologics Corp (高端疫苗) on Wednesday said it plans to begin phase 2 clinical trials next week for its COVID-19 vaccine candidate and expects to apply by the end of June for emergency use authorization for the drug.
The company has started recruiting participants after last week obtaining Food and Drug Administration (FDA) permission to launch the phase 2 trials.
The company plans to recruit 3,700 participants, the most ever in such trials in Taiwan, as it aims to effectively examine the efficacy of its vaccine over the next three months, it said.